{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"17.0","upperLimit":"37.6","value":"26.3"}]}],"title":"Overall Response Rate"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"42.7","upperLimit":"65.7","value":"54.4"}]}],"title":"Disease Control Rate"}],"denoms":[{"counts":[{"groupId":"OG000","value":"57"}],"units":"Participants"}],"description":"Local assessments of tumor response were performed by individual site investigators according to the Revised Response Criteria for Malignant Lymphoma developed in 2007 based on CT and FDG-PET findings. Overall Response Rate was defined as the percentage of participants who achieved CR (disappearance of all evidence of disease) or PR (regression of measurable disease and no new sites) as their best response. Disease Control Rate is defined as the percentage of participants who achieved CR, PR or SD as their best response.","dispersionType":"90% Confidence Interval","groups":[{"description":"SP-02L (darinaparsin for injection): Darinaparsin 300 mg/m2 once daily for 5 consecutive days every 21 days","id":"OG000","title":"SP-02L (Darinaparsin for Injection)"}],"paramType":"NUMBER","populationDescription":"Efficacy analysis set included patients who fulfilled eligibility criteria and who took a tumor response assessment at least one time after the administration of SP-02L (darinaparsin for injection).","reportingStatus":"POSTED","timeFrame":"Local assessments of tumor response were performed at the end of every 3 cycles, and/or at the end of treatment visit. The best response was determined during the entire treatment period. Maximum duration of assessments was 42.4 months.","title":"Tumor Response (Local Assessment)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}